October 12, 2026Understand HRT mood studies by separating prevention, treatment, and withdrawal, with symptom thresholds, safety findings, and mental-health care.- October 12, 2026Understand SURPASS-CVOT event counts, the 95.3% confidence interval, noninferiority versus superiority, and the active dulaglutide comparison.
- October 12, 2026Explore creatine trials in older and postmenopausal women, including strength, lean tissue, bone density, walking, adherence, and fracture evidence.
- October 12, 2026Review randomized testosterone memory results from the Testosterone Trials and TEAAM, with limits, assessment questions, and realistic expectations.
- October 12, 2026Read SURMOUNT-3 results after lifestyle intervention, with clear explanations of participant selection, additional versus total loss, and study limits.
- October 12, 2026Compare the 2025 injection and 2026 oral semaglutide alcohol trials, including mixed endpoints, small samples, safety, and established treatment options.
- October 12, 2026Compare ELITE, KEEPS, and WHI timing evidence, distinguishing artery imaging from heart events and explaining current HRT treatment considerations.
- October 12, 2026Explore two-year STEP 5 and four-year SELECT weight results, plateau meaning, analysis differences, tolerability, and long-term follow-up questions.
- October 12, 2026Separate TRT fatigue, mood, walking, and fall outcomes in the Testosterone Trials, including primary endpoints, secondary analyses, and monitoring.
- October 12, 2026Read long-term WHI breast-cancer counts and absolute rates, separating estrogen alone from CEE plus MPA, treatment duration, and formulation limits.
